Pittsburgh, PA, United States

STERIS Corporation

steris.com
Pittsburgh, PA, United States
SEARCH FILTERS
Time filter
Source Type

New High Level Disinfectant, Prevention™ HLD for the Animal Health & Alternate Care Markets Virox™ Technologies, Inc. the creators of the patented Accelerated Hydrogen Peroxide® (AHP®) technology announced the launch of a new high level disinfectant (HLD) – PREVENTION™ HLD8.  High level disinfectants are used widely used in the Alternate Care, Probeauty and Animal Health markets for reprocessing semi-critical medical devices, such as:  CPAP Masks; Endotracheal Tubes; Endoscopes; Nebulizers; Endoscopes; Otoscope Cones; Speculums; Ultrasound Probes, and other semi-critical devices. Many of these facilities encounter sensitivity issues with the most commonly used high level disinfectants.  PREVENTION™ HLD8 will provide these markets with an environmentally friendly, safer and easier to use product that is non-sensitizing and has virtually no inhalation risks for staff, patients, clients, or animals. “The Accelerated Hydrogen Peroxide® (AHP®) formulation used in PREVENTION™ HLD8 was co-developed with STERIS Corporation,” says Randy Pilon, President, and CEO, Virox Technologies, Inc. “Being able to develop a formulation that provides the perfect balance between safety and efficacy is truly a breakthrough achievement.  We’re excited to bring this formulation to the markets outside of traditional healthcare facilities,” said Pilon. "Finally, there is no longer a need to compromise by using harsh chemistries to reprocess the semi-critical devices health professionals use every day.” PREVENTION™ HLD8 is a 2% AHP® formulation that provides high level disinfection in only 8 minutes and can be re-used for up to 21 days.  In addition, no special venting or disposal measures are needed as the solution can be easily rinsed down the drain.  PREVENTION™ HLD8 is also non-staining, virtually odorless and leaves no toxic residues on devices after just one rinse.  According to Faraz Ahmadpour, Vice President, Open Innovation, “the oxidative action of our AHP® technology does not promote biofilm formation and has excellent materials compatibility with the semi-critical instruments and devices. ” A chemical Indicator test strip (PREVENTION™ HLD8 Test Strip) and log charts are also available to verify and record the correct minimum effective hydrogen peroxide concentration each time reprocessing is performed. PREVENTION™ HLD8 is sold exclusively in the United States. Please visit www.virox.com  for Alternate Care and Probeauty inquiries and  www.viroxanimalhealth.com for veterinary and farm uses, to find a distributor and for more information on how PREVENTION™ HLD8 can improve productivity, resolve OSHA compliance and provide a more environmentally friendly alternative to harsh legacy chemicals. Virox™ Technologies, Inc. is dedicated to infection control through the development of revolutionary disinfectants powered by the patented technology, Accelerated Hydrogen Peroxide® (AHP®), to battle the war against microbes on hands, surfaces, and devices, without the need to compromise on efficacy of application, or to trade off for either personal safety or environmental integrity. A wide variety of products are available exclusively through authorized distributors around the globe.


News Article | June 26, 2017
Site: www.prnewswire.com

"Laurie brings extensive operations, strategy and financial experience to our strong board of directors," said Luke Kissam, Albemarle chairman, president and CEO. "We are excited to have Laurie join our team. She has over 20 years of experience as a leader in various industries including natural resources, which will serve Albemarle and our shareholders well." "I am very pleased to welcome Laurie to the Albemarle board of directors," added Jim Nokes, Albemarle's lead independent director.  "In addition to her industry experience, her financial background and prior experience as a director complement the diverse skills of our board and make her an excellent addition to the committees on which she will serve." Brlas is the former executive vice president and chief financial officer of Newmont Mining Corporation, a position she held from September 2013, until October 2016. She previously served in various leadership roles at Cliffs Natural Resources, Inc., an iron ore producer, from 2006 to 2013, including executive vice president and president of Global Operations.  Prior to Cliffs, Brlas served as senior vice president and chief financial officer of STERIS Corporation.  She currently serves on the board of directors of Perrigo Company and Calpine.  Brlas received her bachelor's degree in Accounting from Youngstown State University in Ohio. About Albemarle Albemarle Corporation (NYSE: ALB), headquartered in Charlotte, NC, is a global specialty chemicals company with leading positions in lithium, bromine and refining catalysts. We power the potential of companies in many of the world's largest and most critical industries, from energy and communications to transportation and electronics.  Working side-by-side with our customers, we develop value-added, customized solutions that make them more competitive. Our solutions combine the finest technology and ingredients with the knowledge and know-how of our highly experienced and talented team of operators, scientists and engineers. Discovering and implementing new and better performance-based sustainable solutions is what motivates all of us. We think beyond business-as-usual to drive innovations that create lasting value. Albemarle employs approximately 4,500 people and serves customers in approximately 100 countries. We regularly post information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, SEC filings and other information regarding our company, its businesses and the markets it serves. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Albemarle Corporation's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/laurie-brlas-elected-to-albemarle-corporation-board-of-directors-300479345.html


News Article | February 16, 2017
Site: www.PR.com

The agenda has been released and registration is now open for SMi’s Pharmaceutical Microbiology USA show. The seventh in its series, this event will take place in San Diego, on the 8th and 9th June 2017. San Diego, CA, February 16, 2017 --( Through a series of presentations from handpicked industry experts, two pre-conference workshops and an additional interactive training session, the agenda will discuss hot topics such as rapid microbiology methods (RMM), risk assessment, challenges in endotoxin recovery, environmental monitoring, sterility assurance, data integrity and much more. Chairs for 2017: - Donald Singer, GSK Fellow, Steriles Microbiology, R&D, GSK - John Duguid, Senior Director, Research & Development, Vericel Corporation Expert Speaker Line-Up: - Ron Smith, Director, External Supply Integration Quality, Janssen - Ren-Yo Forng, Scientific Director, Amgen - Kevin Luongo, QC Sr. Scientist (Microbiology), Takeda - Elizabeth Hulanick, Microbiologist, Renaissance Pharmaceuticals - Paul Ricciatti, Sterility Assurance Manager, Bimeda - Jeanne Moldenhauer, Vice President, Excellent Pharma Consulting - Akua Gilbert-Arthur, Principal Scientist, Roche Molecular Systems - Jarett Scalzo, QC, Microbiology Manager, Kite Pharma Benefits of attending: - Discuss the challenges involved with microbial control with Takeda - Following the path to efficient sterility assurance with GSK - Bimeda highlight the importance of environmental modelling - Delve into the latest developments in rapid microbial methods with Janssen - Hear the latest on data integrity and compliance with Roche - Take part in an interactive extended training session with Microrite Running alongside the conference will be two pre-conference workshops held on the 7th June. Workshop A: Technologies for Monitoring Contamination Control and Case Studies on Contamination Control. Hosted by Jim Polarine Jr, Senior Technical Service Manager, STERIS Corporation and Andrew Bartko, Research Leader, Battelle Memorial Institute. Workshop B: Microbial Required Use for Terminal Sterilization. Hosted by Jerry Dalfors, Principal, JD Technologies For those wanting to attend, there is currently an early bird offer available; book by 28th February to save $300 off the conference price. Register at www.pharma-microbiology-usa.com/prcom Pharmaceutical Microbiology USA is sponsored by Charles River and Rapid Microbiosytems For sponsorship packages: Contact Alia Malick +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk. For delegate enquiries: Contact Fateja Begum on +44 (0) 20 7827 6184 or email fbegum@smi-online.co.uk For media enquiries, contact Zoe Gale on +44 (0) 20 7827 6138 or zgale@smi-online.co.uk Pharmaceutical Microbiology USA 8 - 9 June 2017 San Diego, California, USA www.pharma-microbiology-usa.com/prcom Contact e-mail: zgale@smi-online.co.uk Contact tel: +44 (0) 207 827 6184 #smimicrobiology About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk San Diego, CA, February 16, 2017 --( PR.com )-- Aimed at Microbiologists, Quality Control and Quality Assurance Managers, Pharmaceutical Microbiology USA 2017 will address the current challenges and developing trends of the pharmaceutical microbiology field.Through a series of presentations from handpicked industry experts, two pre-conference workshops and an additional interactive training session, the agenda will discuss hot topics such as rapid microbiology methods (RMM), risk assessment, challenges in endotoxin recovery, environmental monitoring, sterility assurance, data integrity and much more.Chairs for 2017:- Donald Singer, GSK Fellow, Steriles Microbiology, R&D, GSK- John Duguid, Senior Director, Research & Development, Vericel CorporationExpert Speaker Line-Up:- Ron Smith, Director, External Supply Integration Quality, Janssen- Ren-Yo Forng, Scientific Director, Amgen- Kevin Luongo, QC Sr. Scientist (Microbiology), Takeda- Elizabeth Hulanick, Microbiologist, Renaissance Pharmaceuticals- Paul Ricciatti, Sterility Assurance Manager, Bimeda- Jeanne Moldenhauer, Vice President, Excellent Pharma Consulting- Akua Gilbert-Arthur, Principal Scientist, Roche Molecular Systems- Jarett Scalzo, QC, Microbiology Manager, Kite PharmaBenefits of attending:- Discuss the challenges involved with microbial control with Takeda- Following the path to efficient sterility assurance with GSK- Bimeda highlight the importance of environmental modelling- Delve into the latest developments in rapid microbial methods with Janssen- Hear the latest on data integrity and compliance with Roche- Take part in an interactive extended training session with MicroriteRunning alongside the conference will be two pre-conference workshops held on the 7th June.Workshop A: Technologies for Monitoring Contamination Control and Case Studies on Contamination Control. Hosted by Jim Polarine Jr, Senior Technical Service Manager, STERIS Corporation and Andrew Bartko, Research Leader, Battelle Memorial Institute.Workshop B: Microbial Required Use for Terminal Sterilization. Hosted by Jerry Dalfors, Principal, JD TechnologiesFor those wanting to attend, there is currently an early bird offer available; book by 28th February to save $300 off the conference price. Register at www.pharma-microbiology-usa.com/prcomPharmaceutical Microbiology USA is sponsored by Charles River and Rapid MicrobiosytemsFor sponsorship packages: Contact Alia Malick +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk.For delegate enquiries: Contact Fateja Begum on +44 (0) 20 7827 6184 or emailfbegum@smi-online.co.ukFor media enquiries, contact Zoe Gale on +44 (0) 20 7827 6138 or zgale@smi-online.co.ukPharmaceutical Microbiology USA8 - 9 June 2017San Diego, California, USAwww.pharma-microbiology-usa.com/prcomContact e-mail: zgale@smi-online.co.ukContact tel: +44 (0) 207 827 6184#smimicrobiologyAbout SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


Interactive Training Session on Cleanrooms and Environmental Monitoring at Pharmaceutical Microbiology USA SMi Group presents the seventh in its series, Pharmaceutical Microbiology USA will take place in San Diego, on the 8th and 9th June 2017. San Diego, CA, March 01, 2017 --( Morgan Polen the Subject Matter Expert on Contamination Control from Microrite will be hosting the training session on 'Effects of cleanrooms and barrier systems on environmental monitoring data'. Recent warning letters show that manufacturers of aseptic products are receiving the most 483s; many are related to smoke studies. Smoke / Airflow Visualization tests are often performed by third party certifiers. However, per FDA guidance, dynamic in-situ air pattern analysis is more complex. These studies should be investigative and effective at identifying design flaws or airflow issues. They should be performed using the correct type of smoke, smoke density, and camera angles. Therefore this exclusive one hour interactive training session will cover: • Regulations and guidelines related to smoke studies • Types of smoke (and equipment) used for smoke studies-pros and cons • Execution of an investigative smoke study • Case studies with videos of bad airflows and barrier system flaws • Practical demonstration of smoke vs fog • Discussions on 483s related to smoke studies • Mistakes made during environmental monitoring in barriers with inadequate laminar flow that lead to excursions. Alongside hosting the extended training sessions, Microrite will be providing a presentation throughout the two day conference where they will be joined by GSK, Bimeda, Sanofi, Amgen, Excellent Pharma Consulting, Renaissance Pharmaceuticals, Takeda, Vericel Corporation, Roche, Merck and more. All of the speakers have been carefully handpicked to provide insightful presentations from industry experts who will share recent case studies and discuss the developing trends in the field of pharmaceutical microbiology. Running alongside the conference will be two pre-conference workshops held on the 7th June. Workshop A: Technologies for Monitoring Contamination Control and Case Studies on Contamination Control. Hosted by Jim Polarine Jr, Senior Technical Service Manager, STERIS Corporation and Andrew Bartko, Research Leader, Battelle Memorial Institute. Workshop B: Microbial Required Use for Terminal Sterilization. Hosted by Jerry Dalfors, Principal, JD Technologies For those wanting to attend, there is currently an early bird offer available; book by 31st March to save $200 off the conference price. Register at www.pharma-microbiology-usa.com/prcom Pharmaceutical Microbiology USA is sponsored by Charles River and Rapid Microbiosytems For sponsorship packages: Contact Alia Malick +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk. For delegate enquiries: Contact Fateja Begum on +44 (0) 20 7827 6184 or email fbegum@smi-online.co.uk For media enquiries, contact Zoe Gale on +44 (0) 20 7827 6138 or zgale@smi-online.co.uk Pharmaceutical Microbiology USA 8 - 9 June 2017 San Diego, California, USA www.pharma-microbiology-usa.com/prcom Contact e-mail: zgale@smi-online.co.uk Contact tel: +44 (0) 207 827 6184 #smimicrobiology About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk San Diego, CA, March 01, 2017 --( PR.com )-- The 2017 agenda will provide, 16 thought provoking presentations, 17 leading expert speakers, 2 pre-conference workshops and an extended interactive training session.Morgan Polen the Subject Matter Expert on Contamination Control from Microrite will be hosting the training session on 'Effects of cleanrooms and barrier systems on environmental monitoring data'.Recent warning letters show that manufacturers of aseptic products are receiving the most 483s; many are related to smoke studies. Smoke / Airflow Visualization tests are often performed by third party certifiers. However, per FDA guidance, dynamic in-situ air pattern analysis is more complex. These studies should be investigative and effective at identifying design flaws or airflow issues. They should be performed using the correct type of smoke, smoke density, and camera angles. Therefore this exclusive one hour interactive training session will cover:• Regulations and guidelines related to smoke studies• Types of smoke (and equipment) used for smoke studies-pros and cons• Execution of an investigative smoke study• Case studies with videos of bad airflows and barrier system flaws• Practical demonstration of smoke vs fog• Discussions on 483s related to smoke studies• Mistakes made during environmental monitoring in barriers with inadequate laminar flow that lead to excursions.Alongside hosting the extended training sessions, Microrite will be providing a presentation throughout the two day conference where they will be joined by GSK, Bimeda, Sanofi, Amgen, Excellent Pharma Consulting, Renaissance Pharmaceuticals, Takeda, Vericel Corporation, Roche, Merck and more. All of the speakers have been carefully handpicked to provide insightful presentations from industry experts who will share recent case studies and discuss the developing trends in the field of pharmaceutical microbiology.Running alongside the conference will be two pre-conference workshops held on the 7th June.Workshop A: Technologies for Monitoring Contamination Control and Case Studies on Contamination Control. Hosted by Jim Polarine Jr, Senior Technical Service Manager, STERIS Corporation and Andrew Bartko, Research Leader, Battelle Memorial Institute.Workshop B: Microbial Required Use for Terminal Sterilization. Hosted by Jerry Dalfors, Principal, JD TechnologiesFor those wanting to attend, there is currently an early bird offer available; book by 31st March to save $200 off the conference price. Register at www.pharma-microbiology-usa.com/prcomPharmaceutical Microbiology USA is sponsored by Charles River and Rapid MicrobiosytemsFor sponsorship packages: Contact Alia Malick +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk.For delegate enquiries: Contact Fateja Begum on +44 (0) 20 7827 6184 or emailfbegum@smi-online.co.ukFor media enquiries, contact Zoe Gale on +44 (0) 20 7827 6138 or zgale@smi-online.co.ukPharmaceutical Microbiology USA8 - 9 June 2017San Diego, California, USAwww.pharma-microbiology-usa.com/prcomContact e-mail: zgale@smi-online.co.ukContact tel: +44 (0) 207 827 6184#smimicrobiologyAbout SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


Patent
STERIS Corporation | Date: 2016-08-25

An amperometric gas sensor for measuring the concentration of an analyte includes: a solid configured as an insulator without being contacted by the analyte and configured for diffusion of the analyte therethrough, the solid including a non-conductive polymer, the solid further configured to increase in electrical conductivity when in contact with the analyte; a working electrode positioned on and in contact with the solid; and a reference electrode positioned on and in contact with the solid, the reference electrode spaced apart and insulated from the working electrode without the solid being contacted by the analyte, the working electrode and the reference electrode configured to measure electrical conductivity of the solid when the solid is in contact with the analyte.


Reactive compositions are provided, having biocidal and chemical decontamination/neutralization properties, comprising a hygroscopic polymer and an active, which are useful in a variety of commercial, healthcare and military applications and a wide variety of contaminants, including without limitation chemical and biological warfare agents. The reactive compositions are renewable or rechargeable after use by exposure to an additional application of the active and do not require removal, disposal or replacement of the originally applied composition. Methods for preparing and applying the reactive compositions are disclosed.


Patent
STERIS Corporation | Date: 2011-05-25

A self contained unit and system for determining whether medical equipment or devices such as endoscopes, minimally invasive surgical instruments (MIS), etc., are blocked, or substantially free flowing, or are disconnected or leaking before they are subjected to cleaning and/or a disinfecting process that is either sequential or simultaneous. The apparatus has a manifold that generally receives predetermined amounts of a gas and/or liquid for dispensing to one and preferably a plurality of channels. Advantageously, the test apparatus of the present invention can be utilized as a stand-alone unit that is able to monitor the noted medical equipment or devices with regard to the flow of a gas and/or liquid therethrough such as large or small lumens and such flow can also be automatically verified by a system independent of human intervention. Alternatively, the test apparatus can be utilized as part of a comprehensive system in conjunction with other devices for testing, cleaning, and/or disinfecting.


Patent
STERIS Corporation | Date: 2014-09-30

The disclosed invention relates to an amperometric gas sensor for measuring the concentration of an analyte, comprising: a solid support; and a working electrode in contact with the solid support; wherein the analyte comprises a dopant which when in contact with the solid support increases the electrical conductivity of the solid support. A sterilization process employing the amperometric gas sensor is disclosed.


Patent
STERIS Corporation | Date: 2014-09-30

The disclosed invention relates to an amperometric gas sensor for measuring the concentration of an analyte, comprising: a solid support; and a working electrode in contact with the solid support; wherein the analyte comprises a dopant which when in contact with the solid support increases the electrical conductivity of the solid support. A sterilization process employing the amperometric gas sensor is disclosed.


Patent
STERIS Corporation | Date: 2013-02-26

The disclosed invention relates to an amperometric gas sensor for measuring the concentration of an analyte, comprising: a solid support; and a working electrode in contact with the solid support; wherein the analyte comprises a dopant which when in contact with the solid support increases the electrical conductivity of the solid support. A sterilization process employing the amperometric gas sensor is disclosed.

Loading STERIS Corporation collaborators
Loading STERIS Corporation collaborators